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peripheral  structures  of  the  secondary  pulmonary  lobule  and
facilitates  immunohistochemical  staining.  In  addition,  TBLC
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Transbronchial cryobiopsy in
the  diagnosis of desquamative
interstitial pneumonia
Desquamative  interstitial  pneumonia  (DIP)  is  a  rare  interst
tial  pneumonia  usually  associated  with  cigarette  smoke.1
It  is  characterized  by  the  accumulation  of  intra-alveola
macrophages,  sometimes  associated  with  giant  cells.1,3 Th
diagnosis  may  be  suggested  by  patchy  ground-glass  opac
ﬁcation  with  a  predilection  for  the  mid  and  lower  lun
lobes  on  high-resolution  computed  tomography  (HRCT
subpleural  involvement  is  also  typical.  Irregular  lines,  tra
tion  bronchiectasis,  cysts,  emphysema,  and  nodules  ar
other  possible  ﬁndings  of  DIP.4 Bronchoalveolar  lavage  ﬂu
nearly  always  contains  an  increased  number  of  alveola
macrophages.2,4 Histologically,  DIP  is  characterized  by  th
accumulation  of  macrophages  in  the  alveolar  spaces  asso
ciated  with  interstitial  inﬂammation  and/or  ﬁbrosis.  Th
macrophages  usually  contain  light  brown  pigment.  Lympho
nodules  and  a  sparse  but  distinct  eosinophilic  inﬁltrate  ar
common.3 Surgical  lung  biopsy  is  still  required  to  make  
deﬁnitive  diagnosis.1--3
Transbronchial  lung  cryobiopsy  (TBLC)  is  a  new  endo
scopic  technique  that  has  recently  shown  superior  diagnostic
yield  to  conventional  transbronchial  biopsy  (TBB).5--7 The
advantage  of  the  cryoprobe,  compared  with  conventional
TBB  or  TBB  using  jumbo  forceps  is  that  larger  pieces  of  tis-
sue,  without  crush  artifacts,  can  be  extracted  during  the
freeze-thaw  cycle,  allowing  the  identiﬁcation  of  complex
pathologic  patterns.  The  technique  permits  visualization  ofcan  be  performed  on  an  outpatient  basis  and  is  both  an  ea
ier  and  safer  procedure  for  patients  with  comorbidities,  a
it  reduces  the  complications  and  mortality  associated  wit
surgical  lung  biopsy.6
Most  of  the  data  available  to  date  is  on  TBLC  overa
diagnostic  yield  and  complication  rates.5 However,  it  is  als
important  for  clinicians  to  know  the  diagnostic  accuracy  o
TBLC  in  particular  diffuse  lung  diseases,  especially  in  case
in  which  histologic  evaluation  is  an  essential  component  o
multidisciplinary  diagnostic  approach,  as  is  the  case  wit
DIP.
Our  aim  was  to  investigate  the  diagnostic  accuracy  o
TBLC  in  patients  with  clinical  and  radiological  ﬁndingFigure  1  HRCT  scan  showing  ground-glass  pattern  in  the  lower
pulmonary  lobes.
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ure  2  Lung  parenchyma  with  preserved  architecture,  with  aggregates  of  macrophages  within  alveolar  spaces  and  small
nchioles. The  cytoplasm  contains  coarsely  granular  golden  brown  pigment.
mpatible  with  DIP  who  underwent  a  multidisciplinary  diag-
stic  evaluation.
Between  September  2014  and  September  2015,  48
tients  underwent  TBLC  as  part  of  an  interstitial  lung
ease  diagnostic  approach  at  the  pulmonology  depart-
nt  at  Centro  Hospitalar  São  João  in  Porto,  Portugal.  The
tients  were  anesthetized  and  intubated  with  a  rigid  bron-
oscope  under  jet  ventilation.  Endoscopic  exploration  of
 bronchial  tree  was  performed  through  the  endotracheal
e  using  a  video  bronchoscope,  and  a  Fogarty  balloon  was
roduced  into  the  selected  lobe.  Subsequently,  under  ﬂuo-
copic  guidance,  the  transbronchial  biopsy  was  performed
ng  a  ﬂexible  cryoprobe  (2.4  mm  in  diameter  and  900  mm
length).  The  cryoprobe  was  introduced  through  the  ﬂex-
e  bronchoscope  work  channel,  which  was  connected  to
cryosurgical  system  (Erbokryo  CA,  Erbe,  Germany).  The
sue  was  frozen  following  the  Joule-Thomson  principle,
ng  gas  decompression  (carbon  dioxide)  at  the  tip  of  the
be.
TBLC  conﬁrmed  the  diagnosis  of  DIP  in  all  ﬁve  patients
ur  women)  in  whom  this  condition  was  suspected.  Their
an  age  was  45.2  ±  8.5  years  and  they  were  all  active
okers.  Three  of  the  patients  reported  dyspnea  on  exer-
n,  one  reported  dry  cough,  and  one  had  no  relevant
piratory  symptoms.  One  of  the  women  had  systemic
erosis.  Three  patients  had  a  moderate  restrictive  ventila-
y  pattern  (FVC  64.9%  ±  8.2%),  and  all  ﬁve  patients  had
ld  diffusion  capacity  impairment  (DLCO  57.5%  ±  8.4%).
 the  patients  had  a  ground-glass  pattern  with  a  lower-
g  predilection  on  the  thoracic  HRCT  scan  (Fig.  1).  Two
tients  had  eosinophilic  alveolitis  in  the  bronchoalveolar
age  ﬂuid,  while  the  other  three  had  a  higher  total  cell
unt  with  a  normal  differential.
TBLC  was  performed  in  different  segments  of  the  same
e  in  four  patients  (right  lower  lobe  in  three  cases  and
t  lower  lobe  in  one)  and  in  two  lobes  (right  superior
d  lower  lobes)  in  one  patient.  Three  patients  underwent
r  biopsies,  one  underwent  three  biopsies,  and  one  under-
nt  two.  The  mean  size  of  the  samples  was  5  mm  (range,
All  the  patients  had  a deﬁnitive  diagnosis  of  DIP  after
the  ﬁnal  multidisciplinary  diagnostic  evaluation.  The  results
from  this  series  support  previous  ﬁndings  showing  that  TBLC
seems  to  be  a reliable,  effective,  and  safe  diagnostic  tool  for
collecting  a  representative  lung  sample.  TBLC  may  have  a
major  role  in  the  multidisciplinary  work-up  of  DIP,  an  entity
that  has  traditionally  required  surgical  lung  biopsy  for  an
accurate  diagnosis.
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Pleural  metastases  are  more  common  in  the  visceral  pleura
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Hodgkin’s  lymphomas  CD15,  CD30
Metastatic  squamous
carcinoma
Involucrin,  CK5/6
Metastatic  neuroendocrine
tumors
Chromogranin,
Synaptophysin,  NSE,Pleural effusion cytology due to
malignancy. A combined
cytomorphological--immunocytochemical
study of 500 cases
Dear  Editor,
The  ﬁrst  step  in  the  evaluation  of  patients  with  pleural  effu
sion  is  to  determine  whether  the  effusion  is  a  transudat
or  an  exudate.  An  exudative  effusion  is  diagnosed  if  th
patient  meets  Light’s  criteria,  although  new  formulas  hav
been  proposed.1
The  serum  to  pleural  ﬂuid  protein  or  albumin  gradien
may  help  improve  categorization  of  the  occasional  tran
sudate  misidentiﬁed  as  an  exudate  by  these  criteria.  
the  patient  has  a  transudative  effusion,  therapy  should  b
directed  toward  the  underlying  cause  like  heart  failure  o
cirrhosis.  If  the  patient  has  an  exudative  effusion,  attemp
should  be  made  to  deﬁne  the  etiology.  Pneumonia,  can
cer,  tuberculosis,  and  pulmonary  embolism  account  for  mo
exudative  effusions.
Cytomorphology  is  the  hallmark  for  the  diagnosis  o
malignancy.
The  speciﬁcity  of  cytomorphology  is  very  good  and  range
from  91%  to  100%  with  an  average  of  97%.  Sensitivity  range
from  22%  to  81%  with  an  average  of  58.2%.2
Morphologic  distinction  between  reactive  mesotheli
cells  and  malignant  cells  can  be  difﬁcult.  Immunocytochem
istry  is  a  common  adjunct  method  that  serves  to  improv
the  sensitivity  and  speciﬁcity  of  cytology  diagnosis.3 W
used  Ber-EP4  and  calretinin  in  all  malignant  effusions.  Be
EP4  (epithelial  cell  adhesion  molecule)  is  the  most  commo
marker  expressed  in  all  epithelial  cells  but  not  in  mesotheli
and  hematopoietic  cells.4 Calretinin  is  expressed  in  benig
and  malignant  mesothelial  cells  but  not  in  epithelial  cells
Five  hundred  malignant  pleural  effusion  samples  receive
for  cytopathological  examination  from  500  patients  hosp
talized  at  the  University  Hospital  of  Heraklion  Crete  over
5-year  period  were  analyzed  retrospectively.
Table  1  shows  distribution  of  malignancies  in  500  neopla
tic  pleural  effusions.
Table  2  shows  immunocytochemical  markers  expressed  
studied  malignancies.
Cytological  examination  of  pleural  ﬂuids  is  often  the
ﬁrst  line  of  investigation  to  detect  and  type  the  neoplas-
tic  cells  based  on  their  subtle  morphological  features.5and  tend  to  be  focal  in  the  parietal  pleura  which  is  wh
pleural  ﬂuid  cytology  is  a  more  sensitive  diagnostic  test  tha
closed  percutaneous  pleural  biopsy.6
The  most  common  type  of  tumor  to  produce  metast
sis  is  the  broad  group  of  adenocarcinomas,  most  of  the
from  lung,  breast,  ovary  and  GIT.  In  the  present  stud
the  most  frequent  cause  of  malignant  pleural  effusion  wa
lung.  The  neoplastic  cells  showed  classical  features  o
Table  1  Distribution  of  malignancies  in  500  pleural  effusion
specimens.
No  of  neoplastic  pleural
effusions  500
(%)
350  Adenocarcinoma  (lung,
breast,  ovary  and  GIT)
70
50 Hodgkin  and  NHL  (B  and
T)  lymphoma
10
40 Squamous  carcinoma
(lung,  head  and  neck,
larynx,  genital  track)
8
30 Neuroendocrine  tumors
(SCLC)
6
25 Malignant  Melanoma 5
5 Mesothelioma  1
Table  2  Markers  expressed  in  studied  malignancies.
Malignancy  Markers
Metastatic  lung
adenocarcinoma
CK7,  TTF-1
Metastatic  breast  carcinoma  CK19,  Her2  neu,  PR,  ER
receptors
Non-Hodgkin’s  lymphomas PAX5  (PEL,  B-cell  type),
CD4  (T-cell  type)CD56
Malignant  melanoma  HMB45,  Melan-A
Malignant  mesotheliomas  Calretinin,  WT-1
